BC
ASND icon

Brookfield Corp’s Ascendis Pharma A/S ASND Stock Holding History

Brookfield Corp’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,086
Closed -$4.66M – 584
2022
Q3 		$4.66M Buy
+45,086
New +$4.27M 0.02% 287

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Brookfield Corp's ASND Position: Q4 2022 in Review

Brookfield Corp sold out of Ascendis Pharma A/S (ASND) in Q4 2022, closing a stake of 45,086 shares — an estimated $4.66M sold.

Brookfield Corp first reported a position in ASND in Q3 2022 and held it in 1 quarter. The position peaked at $4.66M in Q3 2022. 186 funds tracked by Wall St. Rank hold ASND as of Q4 2022.

  • Brookfield Corp reported no remaining Ascendis Pharma A/S position as of Q4 2022 after selling out during the quarter.
  • Brookfield Corp sold 45,086 Ascendis Pharma A/S shares in Q4 2022, an estimated $4.66M.
  • Brookfield Corp first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 1 quarter.
  • Brookfield Corp's Ascendis Pharma A/S position peaked at $4.66M in Q3 2022.
  • 186 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2022.

Based on Brookfield Corp's 13F filing for Q4 2022, filed 14 Feb 2023.